Annovis Bio, Inc. The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Pennsylvania on behalf of investors who purchased Annovis Bio, Inc. (NYSE: ANVS) securities between May 21, 2021 and July 28, 2021.
According to the Annovis Bio lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Annovis’s ANVS401 (Posiphen), an orally administrated drug which purportedly inhibited the synthesis of neurotoxic proteins that are the main cause of neurodegeneration, did not show statistically significant results across two patient populations as to factors such as orientation, judgement, and problem solving; and (2) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
“Annovis Bio, Inc. “
If you suffered a loss in Annovis Bio you have until October 18, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.